Form 8-K

8-K — MapLight Therapeutics, Inc.

Accession: 0001193125-26-316820

Filed: 2026-07-27

Period: 2026-07-27

CIK: 0001770069

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — d139086d8k.htm (Primary)

EX-99.1 (d139086dex991.htm)

EX-99.2 (d139086dex992.htm)

GRAPHIC (g139086ex99_1p10g1.jpg)

GRAPHIC (g139086ex99_1p11g1.jpg)

GRAPHIC (g139086ex99_1p12g1.jpg)

GRAPHIC (g139086ex99_1p13g1.jpg)

GRAPHIC (g139086ex99_1p14g1.jpg)

GRAPHIC (g139086ex99_1p15g1.jpg)

GRAPHIC (g139086ex99_1p16g1.jpg)

GRAPHIC (g139086ex99_1p17g1.jpg)

GRAPHIC (g139086ex99_1p18g1.jpg)

GRAPHIC (g139086ex99_1p19g1.jpg)

GRAPHIC (g139086ex99_1p1g1.jpg)

GRAPHIC (g139086ex99_1p20g1.jpg)

GRAPHIC (g139086ex99_1p21g1.jpg)

GRAPHIC (g139086ex99_1p22g1.jpg)

GRAPHIC (g139086ex99_1p23g1.jpg)

GRAPHIC (g139086ex99_1p24g1.jpg)

GRAPHIC (g139086ex99_1p25g1.jpg)

GRAPHIC (g139086ex99_1p26g1.jpg)

GRAPHIC (g139086ex99_1p27g1.jpg)

GRAPHIC (g139086ex99_1p2g1.jpg)

GRAPHIC (g139086ex99_1p3g1.jpg)

GRAPHIC (g139086ex99_1p4g1.jpg)

GRAPHIC (g139086ex99_1p5g1.jpg)

GRAPHIC (g139086ex99_1p6g1.jpg)

GRAPHIC (g139086ex99_1p7g1.jpg)

GRAPHIC (g139086ex99_1p8g1.jpg)

GRAPHIC (g139086ex99_1p9g1.jpg)

GRAPHIC (g139086g54o17.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d139086d8k.htm · Sequence: 1

8-K

false 0001770069 0001770069 2026-07-27 2026-07-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 27, 2026

MapLight Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-42914

83-2163243

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

800 Chesapeake Drive

Redwood City, California 94063

(Address of principal executive offices)

Registrant’s telephone number, including area code: (617) 984-6300

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

symbol(s)

Name of each exchange

on which registered

Voting Common Stock, $0.0001 par value per share

MPLT

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On July 27, 2026, MapLight Therapeutics, Inc. (the “Company”) will hold a conference call to discuss the topline results from ZEPHYR, a Phase 2 trial of ML-007C-MA in inpatient adult participants with schizophrenia experiencing an acute exacerbation of psychosis (the “ZEPHYR Trial Results”). A copy of the presentation that will accompany the conference call is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On July 27, 2026, the Company issued a press release announcing the ZEPHYR Trial Results. A copy of this press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

Exhibit Description

99.1

Company Presentation, dated July 27, 2026.

99.2

Press Release, dated July 27, 2026.

104

Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MapLight Therapeutics, Inc.

Dated: July 27, 2026

By:

/s/ Christopher A. Kroeger

Christopher A. Kroeger, M.D.

Chief Executive Officer

EX-99.1

Filename: d139086dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1 Topline Data from Phase 2 ZEPHYR Trial Evaluating

ML-007C-MA in Schizophrenia July 27, 2026

Safe Harbor and Forward-Looking Statements This presentation and any

accompanying oral commentary have been prepared by MapLight Therapeutics, Inc. (“MapLight”, “we,” “us,” “our,” the “Company”, or similar terms) for informational purposes only and not for

any other purpose. This presentation contains trademarks, service marks, trade names and copyrights of MapLight and other companies which are the property of their respective owners. This presentation discusses product candidates that are under

pre-clinical and clinical study, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or efficacy of these product candidates for the uses for which they are being

studied. Statements contained in this presentation and the accompanying oral commentary, other than statements of historical facts, may be forward-looking statements, including, but not limited to statements about the clinical development and

potential benefits, efficacy, and safety of ML-007C-MA , planned regulatory interactions, the availability and timing of reporting results from clinical trials, and our preclinical, clinical and regulatory development plans for product candidates.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,”

“intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these

terms or other similar expressions. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, timing of results, levels of activity, performance, or achievements to be materially

different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties that are described in the “Risk Factors”

section of our Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (“SEC”) on May 14, 2026 and other filings we make with the SEC from time to time. These documents are available under the “SEC

Filings” page of the “Investors” section of our website at www.maplightrx.com. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our

business or the extent to which any factor, or combination of factors, may cause actual results to differ materially and adversely from those anticipated or implied in the forward-looking statements. We may not actually achieve the plans,

intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations

disclosed in the forward-looking statements we make. The forward-looking statements in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change.

However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. Except as required by law, neither we nor any other person

assumes responsibility for the accuracy and completeness of the forward-looking statements in this presentation and the accompanying oral commentary. You should, therefore, not rely on these forward-looking statements as representing our views as of

any date subsequent to the date of this presentation. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. These data involve a number

of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of the future performance of the markets in which we operate are necessarily subject to a high

degree of uncertainty and risk. 2

Agenda Executive Summary and Chris Kroeger, M.D. Co-Founder and Chief

Executive Officer Unmet Medical Need Phase 2 ZEPHYR Erin Foff, M.D., Ph.D. Chief Medical Officer Design and Results Future Development Chris Kroeger, M.D. Co-Founder and Chief Executive Officer Considerations Closing Remarks Chris Kroeger, M.D.

Co-Founder and Chief Executive Officer Q&A Session All 3

ZEPHYR Met Its Primary Endpoint, Supporting Advancement into an

Additional, Confirmatory Pivotal Study • ZEPHYR met its primary endpoint and demonstrated a substantial treatment effect, supported by concordant improvements across key secondary efficacy measures • Robust and clinically meaningful

improvement in cognitive performance observed on a pre- specified secondary endpoint supporting a potentially differentiated clinical profile • Favorable safety and tolerability profile observed, with no serious or drug-related severe adverse

events, low GI-related discontinuation, low rates of moderate GI side-effects, and no urinary retention, metabolic, hepatic, or movement-related signals • Designed for real-world use, with no fasting requirement and a short, one-dose titration

• Data support advancing to an additional pivotal trial to support registration; planning and site identification underway ahead of EOP2 FDA interactions GI = gastrointestinal; EOP2 = end-of-phase 2; FDA = Food and Drug Administration.

Unmet Need in Schizophrenia Remains High Affects Over 20 Million People

Globally, Including More Than 3 Million in the U.S. Patients Remain Underserved by Current SOC ~70% ~30% ~40-50% Antipsychotics… discontinue oral therapies within 18 show no meaningful experience an inadequate months, often due to burdensome

side (1) (1) response to treatment response to standard of care (2) effects (e.g., EPS, weight gain) 2024: First New Mechanism Approved in Decades (Cobenfy) …Yet Significant Cognitive benefit Many patients cannot reach Tolerability burden is

remains unproven or remain at target dose exacerbated in real world Treatment Gaps Still Remain After First Failure to achieve adequate Tolerability challenges observed in Existing evidence is derived from post Muscarinic Approval therapeutic

exposure may leave controlled trials amplified in practice, hoc or exploratory pooled analyses (3) (3) symptoms insufficiently controlled given dosing / fasting complexity across two studies SOC = standard of care; EPS = extrapyramidal symptoms. (1)

Siskind et al., Br J Psychiatry (2022); treatment-resistant≥2 treatments. Samara et al., Schizophrenia Bulletin (2019); response as measured within 4-6 weeks. (2) Lieberman et al., NEJM (2005). CATIE trial; all-cause discontinuation. 5 (3)

BMS. Real-world transition strategies with xanomeline/trospium. Poster, Psych Congress 2025.

Developing a Differentiated Treatment, Designed to Translate into

Real-World Use 210/3 mg BID delivered statistically significant improvement across complementary measures of schizophrenia symptoms • PANSS Total Score (mITT, primary endpoint): Effect Size of 0.37 (-4.5 pts versus placebo, p=0.015) •

PANSS Total Score (Completers): Effect Size of 0.50 (-6.0 pts vs. Placebo, p=0.002) • Also demonstrated significant separation on key secondary endpoints, including CGI-S (ES=0.48) and positive symptoms (ES=0.39) 210/3 mg BID also delivered

significant improvement on cognitive performance, a potentially differentiating component of the clinical profile • Cognitive Composite Score in participants with baseline cognitive impairment (prespecified secondary endpoint): Effect Size of

0.51 (0.44 pts vs. Placebo, p=0.041), assessed via Cogstate battery • No significant correlation observed (p=0.314), indicating the effect was not likely secondary to reduced psychotic symptoms ML-007C-MA was generally well-tolerated, with a

profile designed to translate into real-world use • No serious or drug-related severe AEs: Moderate-or-worse TEAE burden was meaningfully lower for ML-007C-MA than reported in Cobenfy's pivotal trials • Low discontinuation across active

arms (19.9%) • Infrequent BID dose reduction due to TEAEs (4.0%); low rates of discontinuation due to GI AEs (2%), moderate GI AEs, and anticholinergic GI AEs • No metabolic, hepatic, or movement-related signal; no significant

anticholinergic safety signals, including urinary retention • No fasting requirement or complex titration, reducing barriers to adherence outside the controlled trial setting BID = twice-daily; PANSS = Positive and Negative Syndrome Scale;

mITT = Modified Intention-to-Treat; CGI-S = Clinical Global Impression of Severity; ES = effect size; GI = gastrointestinal; TEAE = treatment-emergent adverse event; AE = adverse event. 6 Note: Unless otherwise specified, p-values are nominal,

two-sided. For the 210/3 mg dose, the PANSS total score and CGI-S results met the prespecified multiplicity- adjusted significance threshold.

Phase 2 Design and Results Erin Foff, M.D., Ph.D. | Chief Medical

Officer

ZEPHYR Study Outline Designed and Sized to Serve as a Registrational

Study Blinded Treatment Period Screening Follow-up (Day 1 to 35) Period Period (Day -7 to -1) (Day 36 to 42) Week 1 Week 2 Week 3 Week 4 Week 5 Primary Endpoint Placebo Ÿ (N=104) • N = 307 (1) • Randomized 1:1:1 ML-007C-MA Ÿ

210/3 mg BID Ÿ (N=101) • Sites: 25 (US only) (1) ML-007C-MA Ÿ 330/6 mg QD Ÿ (N=102) • CFB PANSS Total Score at Week 5 Primary Endpoint • 18 to 64 years of age with diagnosis of schizophrenia with MINI • CFB

CGI-S at Week 5 Key Secondary • PANSS 80-120 at screening and baseline Study • CFB PANSS positive Marder factor at Week 5 Endpoints • Score ≥4 for two or more positive symptom items Population • CFB PANSS negative

Marder factor at Week 5 • CGI-S score ≥4 Other Secondary • CFB Cognitive Composite Score at Week 5 in the cognitively • Untreated or recent wash-out of antipsychotics impaired at baseline subgroup (Prespecified) CFB = Change

from baseline; MINI = Mini-International Neuropsychiatric Interview; QD = once-daily. 8 (1) Single-dose titration; reduction of dose permitted once between Week 1 to 3 to 165/3 mg BID or 270/6 mg QD

Demographics & Baseline Characteristics Placebo 210/3 mg BID 330/6

mg QD (1) N = 104 N = 99 N = 102 Demographics Mean Age, years 40 42 40 Male Sex at Birth, n (%) 80 (77%) 69 (70%) 77 (75%) Race, n (%) Black or African American 81 (78%) 73 (74%) 80 (78%) White 17 (16%) 22 (22%) 16 (16%) Other 6 (6%) 4 (4%) 6 (6%)

Baseline Clinical Characteristics: N = 104 N = 99 N = 102 Mean (Standard Deviation) PANSS Total Score 97 (7.9) 96 (7.3) 96 (7.5) PANSS Marder Positive Factor Score 31 (3.7) 30 (3.6) 30 (3.7) PANSS Marder Negative Factor Score 23 (4.4) 24 (4.4) 23

(4.0) CGI-S Score 5 (0.6) 5 (0.6) 5 (0.6) (1) N based on participants in safety set (all participants who were randomized and received at least 1 dose of study drug) 9

Primary Endpoint: PANSS Total Score 210/3 mg BID Met Primary Endpoint

Change From Baseline in PANSS Total Score (LS Mean Difference) 210/3 mg 330/6 mg 0 Placebo BID QD -2 N N=103 N=93 N=98 -4 LS Mean CFB -7.2 -11.7 -10.0 -6 LS Mean Diff -4.5 -2.8 vs. Placebo -8 P-value p=0.015 p=0.110 * -10 Effect Size 0.37 0.23 * *

-12 • ZEPHYR met its primary endpoint: Demonstrated a -14 statistically significant, clinically meaningful 0 1 2 3 4 5 6 Week 1 Week 2 Week 3 Week 4 Week 5 reduction in PANSS total score vs. placebo at Week 5 • 210/3 mg dose is also

being evaluated for the ML-007C-MA ML-007C-MA (1) Placebo treatment of ADP (VISTA study ongoing) 210/3 mg BID 330/6 mg QD *p<0.05 LS = least squares; SE = standard error. Note: Negative treatment deltas favor active treatment; effect size

presented as an absolute value. Analysis based on the mITT population. 10 (1) NCT06887192: Evaluating ML-007C-MA for the treatment of hallucinations and delusions associated with Alzheimer’s Disease Psychosis (ADP) LS Mean CFB (SE) in PANSS

Total Score

Primary Endpoint: PANSS Total Score Robust Effect Demonstrated in

Prespecified Completer Analysis Change From Baseline in PANSS Total Score (LS Mean Difference) Placebo 210/3 mg BID 0 (Completers) (Completers) -2 N N=88 N=73 -4 LS Mean CFB -7.5 -13.4 -6 LS Mean Diff -6.0 -8 vs. Placebo * P-value p=0.002 -10 * * **

Effect Size 0.50 -12 ** ** -14 • The completer analysis excludes modelled -16 assumptions about missing data, relying solely on 0 1 2 3 4 5 6 Week 1 Week 2 Week 3 Week 4 Week 5 observed data from the full assessment period ML-007C-MA

ML-007C-MA • Bigger difference in completer analysis driven Placebo Placebo 210/3 mg BID 210/3 mg BID z mostly by improvement in BID arm, not placebo (mITT) (Completer) (mITT) (Completer) *p<0.05, **p<0.01 MMRM= Mixed model for repeated

measures. Note: Negative treatment deltas favor active treatment; effect size presented as an absolute value. Analysis based on the mITT population. 11 LS Mean CFB (SE) in PANSS Total Score

Key Secondary Endpoint: CGI-S Significant Improvement Corroborates

PANSS Improvement Change From Baseline in CGI-S (LS Mean Difference) 0 -0.1 • Clinically meaningful and statistically -0.2 significant improvement in CGI-S vs. placebo at Week 5 -0.3 – 0.38-point improvement -0.4 -0.5 – -0.75

active vs. -0.36 placebo ** -0.6 (1) – p=0.002 ** -0.7 ** – ES = 0.48 -0.8 • Numerical separation starting at Week 1, with -0.9 statistical significance emerging by Week 3 0 1 2 3 4 5 6 Week 1 Week 2 Week 3 Week 4 Week 5 and

continuing over time ML-007C-MA Placebo 210/3 mg BID **p<0.01 Note: Negative treatment deltas favor active treatment; effect size presented as an absolute value. Analysis based on the mITT population. (1) Multiplicity-adjusted one-sided P value=

0.017 12 LS Mean CFB (SE) in CGI-S

PANSS Positive Symptoms Significant Improvement in PANSS Positive

Marder Factor and Positive Subscale Change From Baseline in PANSS Positive Symptoms (LS Mean Difference) 0 PANSS + PANSS + Placebo Marder Subscale -0.5 -1 N 103 93 93 -1.5 -1.9/-1.9 LS Mean * (Marder/ -3.4 -4.2 -2 CFB Subscale) -2.5 LS Mean Diff *

-1.6 -2.3 vs. Placebo -3 ** P-value p=0.012 p=0.0003 -3.5 * ** ** Effect Size 0.39 0.56 -4 ** -4.5 • Clinically meaningful and statistically significant -5 improvement in PANSS positive symptoms vs. 0 1 2 3 4 5 6 Week 1 Week 2 Week 3 Week 4

Week 5 placebo at Week 5 ML-007C-MA ML-007C-MA • PANSS Positive Marder Factor was a key secondary- Placebo Placebo 210/3 mg BID 210/3 mg BID (Marder Factor) (Subscale) PANSS positive Subscale was prespecified (Marder Factor) (Subscale)

*p<0.05 , **p<0.01 Note: Negative treatment deltas favor active treatment; effect size presented as an absolute value. Analysis based on the mITT population. 13 LS Mean CFB (SE) in PANSS Positive Symptoms

Secondary Endpoint: Cognitive Composite Robust and Clinically

Meaningful Improvement on Cognitive Performance Pre-specified Cognitive Composite Score Results No observed significant relationship between cognitive improvement and PANSS change Cognitive Composite Score Placebo: r=-0.071, p=0.678; BID: r=-0.187,

p=0.314 Placebo 210/3 mg BID N with baseline impairment N=37 N=31 LS Mean Change from 0.11 0.55 Baseline LS Mean Difference vs. 0.44 Placebo P-value p=0.041 Effect Size 0.51 PANSS Total Score CFB to Week 5 ML-007C-MA Placebo 210/3 mg BID Dose used

in VISTA Note: Prespecified Cognitive Composite score derived from Cogstate Battery consisting of 6 individual tests 14 Cognitive Composite Score CFB to Week 5

Implications of Cognitive Signal Beyond ZEPHYR Supports Rationale for

VISTA and Broader Development The Signal Supports the Underlying Biology Cognitive Impairment Remains an Unmet Need • Cognitive impairment is estimated to affect >80% of patients with • The cognitive benefit was observed on a

prespecified secondary (1) schizophrenia endpoint • Cognitive impairment is a major determinant of long-term • Change in the cognitive composite score was independent of functional outcomes, including employment, independent living

changes in PANSS, suggesting it was not simply driven by better and quality of life control of psychotic symptoms • Despite decades of research, no therapies have been approved to • The finding is consistent with the established role of

M1 receptor treat cognitive impairment in schizophrenia activation in learning and memory, strengthening confidence in the underlying mechanism – Highlights both the unmet need and the difficulty of demonstrating meaningful cognitive benefit

– Sedation and dopamine blockade from many SOC antipsychotics may worsen cognition (3) Why This Matters for VISTA and Future Development • A positive cognitive signal observed outside AD increases confidence that the biology translates

across neuropsychiatric populations (2) • Off-label use of antipsychotics in ADP has been associated with accelerated cognitive decline (CATIE-AD), highlighting the need for new therapies • The 210/3 mg BID dose currently being evaluated

in VISTA is the same dose that demonstrated cognitive benefit in ZEPHYR (1) Maroney, Ment Health Clin. 2022. (2) Vigen et al., Am J Psychiatry. 2011. 15 (3) NCT06887192: Evaluating ML-007C-MA for the treatment of hallucinations and delusions

associated with Alzheimer’s Disease Psychosis (ADP).

210/3 mg BID Demonstrated Effect Across Multiple Endpoints and Symptom

Domains N LS Mean Difference [95% CI] Effect Size P-value Active / PBO ← ML-007C-MA favored PBO favored → PANSS Total Score – mITT 93 / 103 0.37 0.015 -10 -8 -6 -4 -2 0 PANSS Total Score - Completers 73 / 88 0.50 0.002 -10 -8 -6 -4

-2 0 CGI-S 93 / 103 0.48 0.002 -0.6 -0.4 -0.2 0 Cognitive Composite 31 / 37 0.51 0.041 1.0 0.8 0.6 0.4 0.2 0 PANSS Marder Positive Factor 93 / 103 0.39 0.012 -3 -2 -1 0 PANSS Marder Negative Factor 93 / 103 0.18 0.244 -3 -2 -1 0 CGI-C 93 / 103 0.47

0.002 -0.8 -0.6 -0.4 -0.2 0 PGI-C 93 / 103 0.38 0.015 -0.8 -0.6 -0.4 -0.2 0 2.4x more likely to achieve ≥30% response on the PANSS total score by Week 5 (p=0.021) Participants on active treatment were, compared to placebo: 2.8x more likely to

be ready for discharge out of the inpatient hospital setting by Week 5 (p=0.002) CGI-C = Clinical Global Impression of Change; PGI-C = Patient Global Impression of Change. 16 Note: Graphed data represent the LS mean difference (ML-007C-MA 210/3 mg

BID − placebo) and 95% confidence intervals

ML-007C-MA Was Generally Well Tolerated • Adverse events,

primarily cholinergic in nature, were mostly mild Adverse Events (1) • No serious or drug-related severe TEAEs occurred with either dose Mostly Mild • The only severe TEAE (pneumonia) was assessed as unrelated to study drug • There

were no instances of failure to reach target dose due to tolerability GI Events Rarely Led • Dose reduction due to TEAE was infrequent (4 participants); TEAEs leading to dose reduction started in the first week, and most (75%) completed

treatment following dose reduction to Discontinuation • Low rates of moderate GI side-effects with BID Dosing • Low rates of discontinuation (2 participants) due to gastrointestinal adverse events • No urinary retention signal

observed: The active and placebo arms each had a single moderate urinary event (UTI) No Signal Across • No metabolic, hepatic, or EPS signals observed: mean weight, glucose, lipid, liver enzyme, and movement-related parameters remained

comparable to placebo Key Safety Domains • Heart rate increases were mild and consistent with the fesoterodine label, with no evidence of significant blood pressure elevation (1) Single serious adverse event occurred in placebo arm was

worsening schizophrenia. 17

Most Adverse Events Were Mild All Cause Discontinuation Was Low at

19.9% Across Active Treatment Arms Rates of TEAEs With BID Dosing GI TEAEs ≥2% in Active Arm and > Placebo Placebo 210/3 mg BID Placebo 210/3 mg BID N=104 N = 99 N=104 N = 99 Discontinuations Mild Moderate Mild Moderate Nausea 6% 0 20% 9%

Due to TEAE 1.0% 7.1% Vomiting 1% 2% 9% 4% Due to GI TEAE 0 2.0% (3) Dyspepsia 0 1% 8% 1% Constipation 3% 0 8% 1% Utilization of Lower Dose (3) Abdominal pain 3% 0 6% 3% Dose Reduction Due to TEAE 1.9% 4.0% Diarrhea 1% 0 5% 0 GERD 2% 0 2% 0 (1)

Inability to Reach Target Dose 0 1% Any TEAE 48.1% 74.7% All GI TEAEs were mild to moderate in severity Mild 36.5% 48.5% • Other TEAEs ≥5% include: headache, salivary hypersecretion, dizziness, hyperhidrosis, Moderate 11.5% 25.3% hot

flushes, somnolence, chills, decreased appetite, tremor, and insomnia (2) Severe TEAE 0 1.0% • Single episode of unrelated hypertension; one episode of orthostatic hypotension observed in each of the placebo and BID dosing arms Serious TEAE

1.0% 0 AE = adverse event. (1) One participant was withdrawn due to baseline (pre-dose) lab findings following titration dose but prior to first target dose. (2) Assessed as unrelated to study drug (pneumonia). (3) Dyspepsia includes dyspepsia and

esophageal discomfort; abdominal pain includes abdominal discomfort, abdominal pain upper, abdominal pain, abdominal pain lower, abdominal distension, and abdominal tenderness 18

Rates of TEAEs for Cobenfy in Pivotal Studies (1) All Cause

Discontinuation Ranged From 25.4%-36.8% at 5 weeks EMERGENT-2 EMERGENT-3 GI TEAEs >2% in Active Arm and > Placebo Cobenfy FDA Label Placebo Active Placebo Active Placebo Active EMERGENT-2/3 Pooled Discontinuations (N=253) (N=251) (2) (2) (3)

(3) Nausea 4% 19% Due to TEAE 5.6% 7.1% 5.5% 6.4% (7) Dyspepsia 5% 18% (4) (4) Due to GI TEAE Not reported 3.2% Not reported 3.2% Constipation 7% 17% Utilization of Lower Dose Vomiting 1% 15% (7) (1) Abdominal Pain 4% 8% Dose Reduction Due to TEAE 0

5.6% 0.8% 0.8% Diarrhea 2% 6% (2) (2) (5) (5) Inability to Reach Target Dose 1.6% 17.5% 9% 21% GERD <1% 5% Any TEAE 58.4% 75.4% 50.0% 70.4% (1) Mild 27.2% 38.1% 25.8% 36.0% (8) • 51%-78% did not complete 1 year of treatment in the

open-label studies (1) Moderate 24.8% 28.6% 20.3% 26.4% (9) • Real-world non-persistence is ~80% by Month 13 (1) Severe TEAE 4.0% 7.1% 2.3% 8.0% (10) • Real-world Patient Experience (N=90) (2) (2) (6) Serious TEAE 1.6% 1.6% 0 0.8%

>2-3x >80% 55% >50% Moderate-or-worse TEAE burden was meaningfully lower for ML-007C-MA (26%) the rates of nausea did not reach the highest received medication had no or only partial than reported in Cobenfy's pivotal trials (34-36%) and

vomiting dose (125/30 mg) for GI events response to intervention (1) Cobenfy FDA Summary Basis of Approval (SBA). (6) EMERGENT-3 topline results, per Karuna Therapeutics press release (March 2023). Active: GERD (n=1). (2) EMERGENT-2 primary

manuscript: Kaul et al., 2024. Pbo: appendicitis(n=1), schizophrenia (n=1). Active: (7) Dyspepsia includes dyspepsia and esophageal discomfort; abdominal pain includes abdominal suicidal ideation (n=2). discomfort, abdominal pain upper, abdominal

pain, abdominal pain lower, and abdominal tenderness. (3) EMERGENT-3 primary manuscript: Kaul et al., 2024. (8) EMERGENT-4 and EMERGENT-5 results, Kaul et al., 2026. (4) Pooled EMERGENT-2 and -3 rate. 8 participants discontinued in the Cobenfy arm

per the SBA (Table 35) (9) Non-persistence: MapLight estimate, third-party Rx data. 19 in the pooled EMERGENT-1,2,3 studies. Per Karuna 2023 10-K filing, only N=2 participants discontinued (10) Retrospective analysis of real-world transition

strategies for xanomeline and trospium chloride in adult from the active arm of EMERGENT-1 (N=89), neither from the GI system organ class. patients with schizophrenia. Poster, Psych Congress 2025. (5) Karuna 2023 10-K filing.

Future Development Considerations Chris Kroeger, M.D. | Co-Founder and

Chief Executive Officer

Significant Opportunity for New Therapies 210/3 mg BID Effect Size

Falls Within the Range of Approved Antipsychotics PANSS Total Score: Standardized Effect Sizes (Cohen’s d) Peak Sales $5.0B $3.2B $3.4B $5.8B $6.2B $2.0B $4.3B $6.0B $2.6B (1) (Year) (2010) (2036E) (2007) (2011) (2013) (2020) (2028E) (2039E)

(2027E) 0.63 0.50 0.48 0.48 0.45 0.56 0.56 0.55 0.42 0.41 0.37 0.36 0.34 0.30 0.26 (0.09) Zyprexa Cobenfy Risperdal Seroquel Abilify ML-007C-MA Latuda Vraylar Caplyta Rexulti (Olanzapine) (KarXT) (Risperidone) (Quetiapine) (Aripiprazole) (210/3mg

BID) (Lurasidone) (Cariprazine) (Lumateperone) (Brexpiprazole) Approved Therapies ML-007C-MA Completers ES (mITT ES) (mITT ES) (Range Shown, if Available) Note: Assessments reflect management’s current views based on publicly available

information and internal analyses; comparisons are subject to uncertainty around interpretation. Differences exist among study designs, and caution should be exercised when comparing data across trials. Sources: Approved antipsychotic effect sizes

per Huhn et al., Lancet 2019; Correll et al., JAMA Psychiatry 2020; Cobenfy per Fabiano et al., 2025 meta-analysis. Completer analysis effect size 21 for Cobenfy estimated based on data from Kaul et al., 2023 and Kaul et al., 2024; Zyprexa and

Latuda based on data from Latuda’s FDA Summary Basis of Approval Tables 37 and 52. Completer/observed-case values reflect trial-completer populations only, not intent-to-treat; ranges reflect variation across available analyses. ML-007C-MA

completer analysis: N=73 (p=0.002). (1) WW consensus peak sales (oral) as per Evaluate Pharma and Visible Alpha as of July 2026; Caplyta projections only available through 2030 (LOE 2039); all indications. Active arm favored → ← PBO

favored

ML-007C-MA Target Product Profile has Potential to be Differentiated

Across Multiple Dimensions In development (2) (3) (4) (1) Cobenfy Emraclidine Direclidine SOC ML-007C-MA Program Antipsychotics M /M Agonist + M PAM M Agonist 1 4 4 4 M /M Agonist + 1 4 Mechanism of Action Peripheral Antagonist Peripheral Antagonist

Primarily D -blockade 2 210/3 mg BID hit Efficacy in RCTs primary endpoint Not stat. sig. in Ph 2 U-shaped dose response Cognitive Prespecified secondary endpoint Improvement Post-hoc/pooled analyses No activity at M No activity at M Some may cause

impairment 1 1 Meaningfully lower rates of significant Tolerability/Safety side effects Moderate to severe TEAEs Metabolic, movement, sedation No Fasting Taken with food Factors expected Requirement Must be taken fasted to impact real world

translation One-dose titration Simple Titration 3-8 day, 2-step titration Varies across APs QD dose to be Dosing Frequency further explored BID Varies across APs RCT = randomized controlled trials; PAM = positive allosteric modulator. Note:

Assessments reflect management’s current views based on publicly available information and internal analyses; comparisons are qualitative and subject to uncertainty around interpretation. Differences exist among study designs, and caution

should be exercised when comparing data across trials. (1) Based on results from ZEPHYR-1 Phase 2 study, and product profile is subject to the completion of additional studies and review by the FDA 22 (2) Based on FDA prescribing information. (3)

Based on results from the Phase 2 EMPOWER-1 and EMPOWER-2 clinical trials, which failed to demonstrate a statistically significant improvement in PANSS total score. (4) Based on results from the Phase 2 clinical trial, which showed statistically

significant improvement only at the lowest dose of the four active drug arms evaluated.

Phase 3 Program and Path to NDA Submission Confirmatory Pivotal Trial

Expected to Support Initial Approval (1) (1) ZEPHYR-2 (Study 311) ZEPHYR-3 (Study 312) ZEPHYR-1 (Study 211) Engage with the FDA Planned Planned at EOP2 Meeting Complete • Similar design to Phase 2, evaluating • Additional pivotal trial

evaluating 210/3 • Established primary efficacy signal and 210/3 mg BID vs. placebo in U.S. sites mg BID safety for 210/3 mg BID • Together with Study 211, intended to • Potential to evaluate an alternate QD • Result supports

pivotal status, pending support initial NDA submission regimen (would pursue as sNDA) confirmation with the FDA VISTA (Study 221) Topline results Ongoing Evaluating potential in additional indications, expected in 2H 2027 including for the treatment

of mild-moderate • Trial in ADP patients evaluating 210/3 Alzheimer’s disease mg BID (potentially registrational) • On track, supported by ZEPHYR's prespecified cognitive signal (1) Subject to FDA feedback at EOP2 Meeting.

Closing Remarks Chris Kroeger, M.D. | Co-Founder and Chief Executive

Officer

Closing Remarks Statistically Significant Across Potentially

Differentiating Tolerability Built for Complementary Measures Cognitive Signal Real-World Use • Met the primary endpoint on PANSS Total • Prespecified Cognitive Composite Score • No serious or drug-related severe adverse Score

(ES=0.37), with a stronger effect in improved significantly (ES=0.51) events; 99% of patients reached the target completers in which there are no modelled dose; low rates of moderate GI side-effects • Cognitive signal independent of

assumptions of missing data (ES=0.50) antipsychotic effect; not a byproduct of • No fasting requirement or complex • Achieved significance on CGI-S and PANSS reduced psychotic symptoms titration, unlike other agents in the class,

Positive Marder Factor potentially increasing adherence and persistence Data support advancement of 210/3 mg BID into a confirmatory pivotal trial and continued investment in indication expansion, leveraging the observed cognitive signal; next steps

will be guided by the planned EOP2 meeting 25

Advancing a Broad and Diversified Pipeline Program Circuit Indications

Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones Engage with FDA at Schizophrenia ZEPHYR EOP2 meeting ML-007C-MA Potential in Direct and Indirect other indications M /M agonist 1 4 Pathways being explored co-formulated with PAC

Alzheimer’s Disease Topline results in 2H 2027 VISTA Psychosis Autism Spectrum Disorder ML-004 Dorsal Raphe to Engage with FDA at IRIS EOP2 meeting Nucleus Accumbens Sociability/Irritability 5-HT agonist 1B/1D ML-009 Complete IND-enabling

studies Indirect Pathway Hyperactivity/Impulsivity in 2027 GPR52 PAM ML-055 Direct and Indirect Nominate preclinical candidate Neuropsychiatric Disorders Pathways in 2026 Next-Gen M /M agonist 1 4 ML-021 Finalize preclinical candidate Direct Pathway

Parkinson’s Disease in 2027 M antagonist 4 Leveraging our versatile circuit-based discovery platform for ongoing pipeline expansion GPR = G-protein-coupled receptor. PAC = peripherally acting anti-cholinergic. PAM = positive allosteric

modulator. 26

Q&A

EX-99.2

Filename: d139086dex992.htm · Sequence: 3

EX-99.2

Exhibit 99.2

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of

ML-007C-MA in Schizophrenia

The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID

dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5 with an effect size of 0.37 (LS mean difference vs PBO -4.5, p=0.015)

Cognitive performance was improved (ES=0.51, p=0.041) in those with baseline cognitive impairment on a prespecified secondary endpoint

210/3 mg BID dose also achieved significant separation on key secondary endpoints, including

CGI-S (ES=0.48, p=0.002) and PANSS Positive Marder Factor (ES=0.39, p=0.012)

ML-007C-MA was generally well tolerated at both doses studied, with no serious or drug-related severe adverse events and low rates of

GI-related discontinuations

No fasting requirement and a

one-dose titration support a tolerability profile expected to translate into real-world adherence

Data support proceeding with an additional trial, also designed to be registrational, to replicate this result; Company to engage with FDA

at End-of-Phase 2 Meeting

Company to host live

webcast today at 8:00 AM ET

SAN FRANCISCO and BOSTON, July 27, 2026 (GLOBE NEWSWIRE) — MapLight Therapeutics, Inc.

(Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced positive topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA, an oral M1/M4 muscarinic agonist (betovumeline) co-formulated with a peripherally acting anticholinergic (fesoterodine), in

adults with an acute exacerbation of schizophrenia. The trial met its primary endpoint, with the 210/3 mg twice-daily (BID) dose demonstrating a statistically significant and clinically meaningful reduction in Positive and Negative Syndrome Scale

(PANSS) total score compared to placebo at Week 5.

In the modified

intent-to-treat (mITT) population, the BID arm achieved an effect size of 0.37 (Cohen’s d) and these participants experienced a mean 4.5-point improvement in PANSS total score versus placebo (p=0.015). In a prespecified analysis of participants who completed five weeks of treatment, in which there are no modelled assumptions for missing data, the

effect size was 0.50 (LS mean difference from placebo -6.0, p=0.002), driven by greater improvement in the treatment arm rather than the placebo arm. ML-007C-MA also achieved significance on key secondary endpoints in the BID arm, including Clinical Global Impression of Severity (CGI-S) (effect size=0.48; p=0.002),

PANSS positive Marder factor (effect size=0.39; p=0.012), and multiple other secondary and exploratory outcomes.

Notably, ML-007C-MA

demonstrated a robust and clinically meaningful improvement in cognitive performance in the BID arm, based on the pre-specified secondary endpoint assessed via the Cogstate battery in participants with

baseline cognitive impairment (effect size=0.51; 0.44 points versus placebo; p=0.041). This cognitive benefit did not demonstrate correlation with the change in PANSS score, suggesting the effect was independent of, and not secondary to, improvement

in psychotic symptoms.

“We are very encouraged by these results, which show that

ML-007C-MA delivered clinically meaningful antipsychotic efficacy alongside a favorable tolerability profile designed to translate into real-world use,” said Chris

Kroeger, M.D., Co-Founder and Chief Executive Officer of MapLight. “Just as importantly, we observed a robust signal on a pre-specified secondary cognition

endpoint that appears independent of antipsychotic effect. Cognitive impairment affects the majority of people living with schizophrenia and remains an area where no therapy has yet been approved. We believe the combination of a significant effect

on PANSS and other concordant endpoints, along with a meaningful effect on cognitive performance, represents a powerful, comprehensive overall efficacy profile in schizophrenia, and strengthens the rationale for our ongoing VISTA trial in

Alzheimer’s disease psychosis and the broader indication expansion for ML-007C-MA.”

The 330/6 mg once-daily (QD) dose, which results in lower daily exposure than BID dosing, demonstrated numerical improvement over placebo, but did not achieve

statistical significance on the primary endpoint. However, it did demonstrate separation on CGI-S (p=0.036), PANSS positive Marder factor (p=0.045), and Readiness for Discharge Questionnaire (p=0.027) and

numerical separation on several other endpoints. The Company is conducting further analyses to inform the potential path forward for a once-daily regimen.

Safety and Tolerability

ML-007C-MA was generally well tolerated across all doses studied.

Treatment-emergent adverse events (TEAEs) were mostly mild and primarily cholinergic in nature, and there were no serious adverse events or drug-related severe TEAEs with either dose. The only severe TEAE in an active arm was a case of pneumonia,

which was assessed as unrelated to study treatment. One serious TEAE of worsening schizophrenia occurred in the placebo arm. All-cause discontinuation across both active arms was low, at 19.9%.

At the 210/3 mg BID dose, TEAEs were reported in 74.7% of participants compared with 48.1% receiving placebo, with most events mild in severity.

Gastrointestinal events were mostly mild and rarely associated with discontinuation (two participants, 2.0%), and there were low rates of moderate GI events. No participant failed to reach target dose due to tolerability, and dose reductions due to

TEAEs were infrequent (four participants, or 4.0%, three of whom completed treatment).

The rates of anticholinergic events were low, and no clinically meaningful signals were observed with ML-007C-MA for urinary retention, metabolic or hepatic parameters, extrapyramidal symptoms, or blood pressure. Small increases in heart rate were observed, consistent with the

known profile of fesoterodine. With no fasting requirement and a short, one-dose titration, these clinical trial results are expected to translate into real-world use, supporting patient adherence and

compliance. “Despite recent advances in schizophrenia treatment, patients and clinicians continue to need therapies that pair meaningful symptom control with a tolerability profile patients can sustain over time,” said John M. Kane,

M.D., Professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Co-Director of the Institute for Behavioral Science at the Feinstein Institutes

for Medical Research, and member of MapLight Therapeutics’ Clinical Advisory Board. “The ZEPHYR results are notable on both fronts: a statistically significant improvement on the primary endpoint and cognitive performance, alongside a

meaningfully differentiated safety profile that matters most for the management of patients over time. If confirmed in a further study and approved, ML-007C-MA could

offer physicians a valuable additional tool in the treatment arsenal for people living with schizophrenia.”

Future Development

The Company plans to engage with the FDA at an End-of-Phase 2 (EOP2) meeting to

discuss the path forward for ML-007C-MA in schizophrenia, including the design of a Phase 3 trial which, together with ZEPHYR, would support an initial New Drug

Application (NDA) submission. Planning and site identification for this additional, confirmatory trial are already underway ahead of the MapLight’s EOP2 FDA interactions. The Company is also planning a separate confirmatory trial to evaluate

the BID dose used in ZEPHYR along with other dosing regimens, including a possible QD option. VISTA, MapLight’s ongoing trial designed to support registration for the treatment of hallucinations and delusions associated with Alzheimer’s

disease psychosis, is also evaluating ML-007C-MA 210/3 mg BID (the same dose associated with the cognitive effect in ZEPHYR), with topline results expected in the second

half of 2027.

Additionally, the Company recently reported results for IRIS, a Phase 2 trial evaluating ML-004, an

5-HT1B/1D agonist in autism spectrum disorder (ASD), where a prespecified subgroup analysis in adolescents with significant baseline irritability

demonstrated meaningful improvement over placebo on both caregiver- and clinician-rated scales alongside a favorable safety and tolerability profile. Based on these results, the Company intends to engage with the FDA in an EOP2 meeting to determine

the next steps for development of ML-004 in irritability associated with ASD.

Live Webcast

The Company will host a live webcast to discuss the Phase 2 ZEPHYR trial results today, Monday, July 27, 2026, at 8:00 a.m. ET. Those who would like to

participate may access the live webcast here, or register in advance for the teleconference here.

The event will also be accessible through

the “Events and Presentations” page within the Investors section of the Maplight website at https://ir.maplightrx.com/news-events/events-presentations. An archived replay will also be available on the website for at least 90 days

following the event.

About ZEPHYR

ZEPHYR is a

randomized, double-blind, placebo-controlled trial at 25 US sites that evaluated the efficacy, safety, and tolerability of ML-007C-MA in inpatient adult participants

with schizophrenia experiencing an acute exacerbation of psychosis. A total of 307 participants were randomized 1:1:1 to receive either placebo, ML-007C-MA 210/3 mg

twice daily, or ML-007C-MA 330/6 mg once daily. The primary endpoint for the trial was the change in PANSS total score from baseline to Week 5. Key secondary endpoints

included change in CGI-S score and PANSS-Marder positive and negative factor scores from baseline to Week 5. Change in cognitive function in participants with baseline cognitive impairment from baseline to

Week 5 was assessed as a prespecified secondary endpoint.

About

ML-007C-MA

ML-007C-MA is an oral, extended-release, fixed-dose combination of the investigational M1/M4 muscarinic agonist ML-007 (betovumeline),

co-formulated with a peripherally acting anticholinergic (fesoterodine). ML-007C-MA is designed to activate both M1 and M4

muscarinic receptors in the central nervous system to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects.

About MapLight Therapeutics

MapLight Therapeutics is a

clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to

address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for

therapeutic modulation.

For more information, please visit www.maplightrx.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including,

but not limited to, the clinical development and potential benefits of ML-007C-MA and ML-004, the design, timing and

conducting of future clinical trials, the registrational pathway for the Company’s product candidates, including holding EOP2 meetings with the FDA for ML-007C-MA

and ML-004 and planned regulatory submissions, the availability and timing of results from the Company’s Phase 2 VISTA trial, and the potential benefits of the Company’s discovery

platform. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,”

“believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, are intended to identify

forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date

of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in the Company’s filings with the U.S.

Securities and Exchange Commission (SEC)), many of which are beyond the Company’s control and subject to change. Actual results could be materially different. Risks and uncertainties include: the unpredictable relationship between preclinical

study results and clinical study results; the risk that results obtained in any clinical trials to date may not be indicative of results obtained in ongoing or future trials; the timing or likelihood of regulatory filings and approvals; expectations

regarding the Company’s ability to fund its current operations; and other risks and uncertainties identified in the Company’s Quarterly Report on Form 10-Q for the quarter ended

March 31, 2026, and subsequent disclosure documents the Company may file with the SEC. The Company claims the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The

Company expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

For investor inquiries: investors@maplightrx.com

For media inquiries: media@maplightrx.com

GRAPHIC

Filename: g139086ex99_1p10g1.jpg · Sequence: 7

Binary file (303680 bytes)

Download g139086ex99_1p10g1.jpg

GRAPHIC

Filename: g139086ex99_1p11g1.jpg · Sequence: 8

Binary file (306799 bytes)

Download g139086ex99_1p11g1.jpg

GRAPHIC

Filename: g139086ex99_1p12g1.jpg · Sequence: 9

Binary file (254318 bytes)

Download g139086ex99_1p12g1.jpg

GRAPHIC

Filename: g139086ex99_1p13g1.jpg · Sequence: 10

Binary file (318754 bytes)

Download g139086ex99_1p13g1.jpg

GRAPHIC

Filename: g139086ex99_1p14g1.jpg · Sequence: 11

Binary file (267695 bytes)

Download g139086ex99_1p14g1.jpg

GRAPHIC

Filename: g139086ex99_1p15g1.jpg · Sequence: 12

Binary file (454859 bytes)

Download g139086ex99_1p15g1.jpg

GRAPHIC

Filename: g139086ex99_1p16g1.jpg · Sequence: 13

Binary file (362752 bytes)

Download g139086ex99_1p16g1.jpg

GRAPHIC

Filename: g139086ex99_1p17g1.jpg · Sequence: 14

Binary file (319844 bytes)

Download g139086ex99_1p17g1.jpg

GRAPHIC

Filename: g139086ex99_1p18g1.jpg · Sequence: 15

Binary file (344629 bytes)

Download g139086ex99_1p18g1.jpg

GRAPHIC

Filename: g139086ex99_1p19g1.jpg · Sequence: 16

Binary file (407819 bytes)

Download g139086ex99_1p19g1.jpg

GRAPHIC

Filename: g139086ex99_1p1g1.jpg · Sequence: 17

Binary file (246031 bytes)

Download g139086ex99_1p1g1.jpg

GRAPHIC

Filename: g139086ex99_1p20g1.jpg · Sequence: 18

Binary file (314588 bytes)

Download g139086ex99_1p20g1.jpg

GRAPHIC

Filename: g139086ex99_1p21g1.jpg · Sequence: 19

Binary file (353881 bytes)

Download g139086ex99_1p21g1.jpg

GRAPHIC

Filename: g139086ex99_1p22g1.jpg · Sequence: 20

Binary file (424420 bytes)

Download g139086ex99_1p22g1.jpg

GRAPHIC

Filename: g139086ex99_1p23g1.jpg · Sequence: 21

Binary file (326100 bytes)

Download g139086ex99_1p23g1.jpg

GRAPHIC

Filename: g139086ex99_1p24g1.jpg · Sequence: 22

Binary file (289388 bytes)

Download g139086ex99_1p24g1.jpg

GRAPHIC

Filename: g139086ex99_1p25g1.jpg · Sequence: 23

Binary file (331140 bytes)

Download g139086ex99_1p25g1.jpg

GRAPHIC

Filename: g139086ex99_1p26g1.jpg · Sequence: 24

Binary file (307181 bytes)

Download g139086ex99_1p26g1.jpg

GRAPHIC

Filename: g139086ex99_1p27g1.jpg · Sequence: 25

Binary file (102743 bytes)

Download g139086ex99_1p27g1.jpg

GRAPHIC

Filename: g139086ex99_1p2g1.jpg · Sequence: 26

Binary file (571576 bytes)

Download g139086ex99_1p2g1.jpg

GRAPHIC

Filename: g139086ex99_1p3g1.jpg · Sequence: 27

Binary file (162595 bytes)

Download g139086ex99_1p3g1.jpg

GRAPHIC

Filename: g139086ex99_1p4g1.jpg · Sequence: 28

Binary file (393330 bytes)

Download g139086ex99_1p4g1.jpg

GRAPHIC

Filename: g139086ex99_1p5g1.jpg · Sequence: 29

Binary file (359304 bytes)

Download g139086ex99_1p5g1.jpg

GRAPHIC

Filename: g139086ex99_1p6g1.jpg · Sequence: 30

Binary file (451796 bytes)

Download g139086ex99_1p6g1.jpg

GRAPHIC

Filename: g139086ex99_1p7g1.jpg · Sequence: 31

Binary file (296104 bytes)

Download g139086ex99_1p7g1.jpg

GRAPHIC

Filename: g139086ex99_1p8g1.jpg · Sequence: 32

Binary file (307500 bytes)

Download g139086ex99_1p8g1.jpg

GRAPHIC

Filename: g139086ex99_1p9g1.jpg · Sequence: 33

Binary file (253763 bytes)

Download g139086ex99_1p9g1.jpg

GRAPHIC

Filename: g139086g54o17.jpg · Sequence: 34

Binary file (869 bytes)

Download g139086g54o17.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 36

v3.26.1

Document and Entity Information

Jul. 27, 2026

Cover [Abstract]

Amendment Flag

false

Entity Central Index Key

0001770069

Document Type

8-K

Document Period End Date

Jul. 27, 2026

Entity Registrant Name

MapLight Therapeutics, Inc.

Entity Incorporation State Country Code

Entity File Number

001-42914

Entity Tax Identification Number

83-2163243

Entity Address, Address Line One

800 Chesapeake Drive

Entity Address, City or Town

Redwood City

Entity Address, State or Province

Entity Address, Postal Zip Code

94063

City Area Code

(617)

Local Phone Number

984-6300

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Voting Common Stock, $0.0001 par value per share

Trading Symbol

MPLT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Entity Ex Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration